ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Non-Small Cell Lung Cancer Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-33S12067
Home | Market Reports | Health| Health Conditions| Cancer
Global Drugs for Non Small Cell Lung Cancer Industry Research Report Growth Trends and Competitive Analysis 2022 2028
BUY CHAPTERS

Global Drugs for Non-Small Cell Lung Cancer Market Research Report 2025

Code: QYRE-Auto-33S12067
Report
September 2025
Pages:107
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bristol–Myers Squibb
GlaxoSmithKline PLC
Menarini
Sanofi
ZIOPHARM Oncology
Alchemia
Amgen Inc
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla Ltd
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis Inc
Fresenius Kabi
Genentech Inc
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals

Drugs for Non-Small Cell Lung Cancer Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Drugs for Non-Small Cell Lung Cancer Market

Drugs for Non-Small Cell Lung Cancer Market

The global market for Drugs for Non-Small Cell Lung Cancer was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Non-Small Cell Lung Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Non-Small Cell Lung Cancer.
The Drugs for Non-Small Cell Lung Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Non-Small Cell Lung Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Non-Small Cell Lung Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Drugs for Non-Small Cell Lung Cancer Market Report

Report Metric Details
Report Name Drugs for Non-Small Cell Lung Cancer Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospitals
  • Clinics
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, Ziopharm Oncology, Alchemia, Amgen, Apotex, BioMarin Pharmaceutical, CellAct Pharma, Cerulean Pharma, Cipla, Cornerstone Pharmaceuticals, Curis, CytRx, Eli Lilly, Exelixis, Fresenius Kabi, Genentech, Hikma Pharmaceuticals, Hospira, Intas Pharmaceuticals, Karyopharm Therapeutics, Kyowa Hakko Kirin, Ligand Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Drugs for Non-Small Cell Lung Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Drugs for Non-Small Cell Lung Cancer Market report?

Ans: The main players in the Drugs for Non-Small Cell Lung Cancer Market are Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, Ziopharm Oncology, Alchemia, Amgen, Apotex, BioMarin Pharmaceutical, CellAct Pharma, Cerulean Pharma, Cipla, Cornerstone Pharmaceuticals, Curis, CytRx, Eli Lilly, Exelixis, Fresenius Kabi, Genentech, Hikma Pharmaceuticals, Hospira, Intas Pharmaceuticals, Karyopharm Therapeutics, Kyowa Hakko Kirin, Ligand Pharmaceuticals

What are the Application segmentation covered in the Drugs for Non-Small Cell Lung Cancer Market report?

Ans: The Applications covered in the Drugs for Non-Small Cell Lung Cancer Market report are Hospitals, Clinics, Other

What are the Type segmentation covered in the Drugs for Non-Small Cell Lung Cancer Market report?

Ans: The Types covered in the Drugs for Non-Small Cell Lung Cancer Market report are Radiofrequency Ablation (RFA), Radiation Therapy, Chemotherapy, Targeted Therapies, Immunotherapy

Recommended Reports

Lung Cancer Drugs

Cancer Therapeutics

Other Oncology Drugs

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Radiofrequency Ablation (RFA)
1.2.3 Radiation Therapy
1.2.4 Chemotherapy
1.2.5 Targeted Therapies
1.2.6 Immunotherapy
1.3 Market by Application
1.3.1 Global Drugs for Non-Small Cell Lung Cancer Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Non-Small Cell Lung Cancer Market Perspective (2020-2031)
2.2 Global Drugs for Non-Small Cell Lung Cancer Growth Trends by Region
2.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Drugs for Non-Small Cell Lung Cancer Historic Market Size by Region (2020-2025)
2.2.3 Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2026-2031)
2.3 Drugs for Non-Small Cell Lung Cancer Market Dynamics
2.3.1 Drugs for Non-Small Cell Lung Cancer Industry Trends
2.3.2 Drugs for Non-Small Cell Lung Cancer Market Drivers
2.3.3 Drugs for Non-Small Cell Lung Cancer Market Challenges
2.3.4 Drugs for Non-Small Cell Lung Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue
3.1.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue (2020-2025)
3.1.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Players (2020-2025)
3.2 Global Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Drugs for Non-Small Cell Lung Cancer Revenue
3.4 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio
3.4.1 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Non-Small Cell Lung Cancer Revenue in 2024
3.5 Global Key Players of Drugs for Non-Small Cell Lung Cancer Head office and Area Served
3.6 Global Key Players of Drugs for Non-Small Cell Lung Cancer, Product and Application
3.7 Global Key Players of Drugs for Non-Small Cell Lung Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Type
4.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Type (2020-2025)
4.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2026-2031)
5 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Application
5.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Application (2020-2025)
5.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Drugs for Non-Small Cell Lung Cancer Market Size (2020-2031)
6.2 North America Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2020-2025)
6.4 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size (2020-2031)
7.2 Europe Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2020-2025)
7.4 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size (2020-2031)
8.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2020-2025)
8.4 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size (2020-2031)
9.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2020-2025)
9.4 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size (2020-2031)
10.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2020-2025)
10.4 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.2.5 GlaxoSmithKline Recent Development
11.3 Menarini
11.3.1 Menarini Company Details
11.3.2 Menarini Business Overview
11.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Introduction
11.3.4 Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.3.5 Menarini Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Introduction
11.4.4 Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.4.5 Sanofi Recent Development
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Details
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.5.5 Ziopharm Oncology Recent Development
11.6 Alchemia
11.6.1 Alchemia Company Details
11.6.2 Alchemia Business Overview
11.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Introduction
11.6.4 Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.6.5 Alchemia Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Introduction
11.7.4 Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.7.5 Amgen Recent Development
11.8 Apotex
11.8.1 Apotex Company Details
11.8.2 Apotex Business Overview
11.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Introduction
11.8.4 Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.8.5 Apotex Recent Development
11.9 BioMarin Pharmaceutical
11.9.1 BioMarin Pharmaceutical Company Details
11.9.2 BioMarin Pharmaceutical Business Overview
11.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Introduction
11.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.9.5 BioMarin Pharmaceutical Recent Development
11.10 CellAct Pharma
11.10.1 CellAct Pharma Company Details
11.10.2 CellAct Pharma Business Overview
11.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.10.4 CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.10.5 CellAct Pharma Recent Development
11.11 Cerulean Pharma
11.11.1 Cerulean Pharma Company Details
11.11.2 Cerulean Pharma Business Overview
11.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.11.4 Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.11.5 Cerulean Pharma Recent Development
11.12 Cipla
11.12.1 Cipla Company Details
11.12.2 Cipla Business Overview
11.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Introduction
11.12.4 Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.12.5 Cipla Recent Development
11.13 Cornerstone Pharmaceuticals
11.13.1 Cornerstone Pharmaceuticals Company Details
11.13.2 Cornerstone Pharmaceuticals Business Overview
11.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.13.5 Cornerstone Pharmaceuticals Recent Development
11.14 Curis
11.14.1 Curis Company Details
11.14.2 Curis Business Overview
11.14.3 Curis Drugs for Non-Small Cell Lung Cancer Introduction
11.14.4 Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.14.5 Curis Recent Development
11.15 CytRx
11.15.1 CytRx Company Details
11.15.2 CytRx Business Overview
11.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Introduction
11.15.4 CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.15.5 CytRx Recent Development
11.16 Eli Lilly
11.16.1 Eli Lilly Company Details
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Introduction
11.16.4 Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.16.5 Eli Lilly Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Details
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Introduction
11.17.4 Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.17.5 Exelixis Recent Development
11.18 Fresenius Kabi
11.18.1 Fresenius Kabi Company Details
11.18.2 Fresenius Kabi Business Overview
11.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Introduction
11.18.4 Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.18.5 Fresenius Kabi Recent Development
11.19 Genentech
11.19.1 Genentech Company Details
11.19.2 Genentech Business Overview
11.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Introduction
11.19.4 Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.19.5 Genentech Recent Development
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Details
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.20.5 Hikma Pharmaceuticals Recent Development
11.21 Hospira
11.21.1 Hospira Company Details
11.21.2 Hospira Business Overview
11.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Introduction
11.21.4 Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.21.5 Hospira Recent Development
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Details
11.22.2 Intas Pharmaceuticals Business Overview
11.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.22.5 Intas Pharmaceuticals Recent Development
11.23 Karyopharm Therapeutics
11.23.1 Karyopharm Therapeutics Company Details
11.23.2 Karyopharm Therapeutics Business Overview
11.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Introduction
11.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.23.5 Karyopharm Therapeutics Recent Development
11.24 Kyowa Hakko Kirin
11.24.1 Kyowa Hakko Kirin Company Details
11.24.2 Kyowa Hakko Kirin Business Overview
11.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Introduction
11.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.24.5 Kyowa Hakko Kirin Recent Development
11.25 Ligand Pharmaceuticals
11.25.1 Ligand Pharmaceuticals Company Details
11.25.2 Ligand Pharmaceuticals Business Overview
11.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
11.25.5 Ligand Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Bristol–Myers Squibb
GlaxoSmithKline PLC
Menarini
Sanofi
ZIOPHARM Oncology
Alchemia
Amgen Inc
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla Ltd
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis Inc
Fresenius Kabi
Genentech Inc
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
List of Tables
 Table 1. Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Radiofrequency Ablation (RFA)
 Table 3. Key Players of Radiation Therapy
 Table 4. Key Players of Chemotherapy
 Table 5. Key Players of Targeted Therapies
 Table 6. Key Players of Immunotherapy
 Table 7. Global Drugs for Non-Small Cell Lung Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region (2020-2025)
 Table 11. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region (2026-2031)
 Table 13. Drugs for Non-Small Cell Lung Cancer Market Trends
 Table 14. Drugs for Non-Small Cell Lung Cancer Market Drivers
 Table 15. Drugs for Non-Small Cell Lung Cancer Market Challenges
 Table 16. Drugs for Non-Small Cell Lung Cancer Market Restraints
 Table 17. Global Drugs for Non-Small Cell Lung Cancer Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Drugs for Non-Small Cell Lung Cancer Market Share by Players (2020-2025)
 Table 19. Global Top Drugs for Non-Small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2024)
 Table 20. Ranking of Global Top Drugs for Non-Small Cell Lung Cancer Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Drugs for Non-Small Cell Lung Cancer, Headquarters and Area Served
 Table 23. Global Key Players of Drugs for Non-Small Cell Lung Cancer, Product and Application
 Table 24. Global Key Players of Drugs for Non-Small Cell Lung Cancer, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Type (2020-2025)
 Table 28. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Type (2026-2031)
 Table 30. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Application (2020-2025)
 Table 32. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Application (2026-2031)
 Table 34. North America Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Bristol-Myers Squibb Company Details
 Table 50. Bristol-Myers Squibb Business Overview
 Table 51. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product
 Table 52. Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 53. Bristol-Myers Squibb Recent Development
 Table 54. GlaxoSmithKline Company Details
 Table 55. GlaxoSmithKline Business Overview
 Table 56. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product
 Table 57. GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 58. GlaxoSmithKline Recent Development
 Table 59. Menarini Company Details
 Table 60. Menarini Business Overview
 Table 61. Menarini Drugs for Non-Small Cell Lung Cancer Product
 Table 62. Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 63. Menarini Recent Development
 Table 64. Sanofi Company Details
 Table 65. Sanofi Business Overview
 Table 66. Sanofi Drugs for Non-Small Cell Lung Cancer Product
 Table 67. Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 68. Sanofi Recent Development
 Table 69. Ziopharm Oncology Company Details
 Table 70. Ziopharm Oncology Business Overview
 Table 71. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product
 Table 72. Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 73. Ziopharm Oncology Recent Development
 Table 74. Alchemia Company Details
 Table 75. Alchemia Business Overview
 Table 76. Alchemia Drugs for Non-Small Cell Lung Cancer Product
 Table 77. Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 78. Alchemia Recent Development
 Table 79. Amgen Company Details
 Table 80. Amgen Business Overview
 Table 81. Amgen Drugs for Non-Small Cell Lung Cancer Product
 Table 82. Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 83. Amgen Recent Development
 Table 84. Apotex Company Details
 Table 85. Apotex Business Overview
 Table 86. Apotex Drugs for Non-Small Cell Lung Cancer Product
 Table 87. Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 88. Apotex Recent Development
 Table 89. BioMarin Pharmaceutical Company Details
 Table 90. BioMarin Pharmaceutical Business Overview
 Table 91. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product
 Table 92. BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 93. BioMarin Pharmaceutical Recent Development
 Table 94. CellAct Pharma Company Details
 Table 95. CellAct Pharma Business Overview
 Table 96. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product
 Table 97. CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 98. CellAct Pharma Recent Development
 Table 99. Cerulean Pharma Company Details
 Table 100. Cerulean Pharma Business Overview
 Table 101. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product
 Table 102. Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 103. Cerulean Pharma Recent Development
 Table 104. Cipla Company Details
 Table 105. Cipla Business Overview
 Table 106. Cipla Drugs for Non-Small Cell Lung Cancer Product
 Table 107. Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 108. Cipla Recent Development
 Table 109. Cornerstone Pharmaceuticals Company Details
 Table 110. Cornerstone Pharmaceuticals Business Overview
 Table 111. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
 Table 112. Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 113. Cornerstone Pharmaceuticals Recent Development
 Table 114. Curis Company Details
 Table 115. Curis Business Overview
 Table 116. Curis Drugs for Non-Small Cell Lung Cancer Product
 Table 117. Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 118. Curis Recent Development
 Table 119. CytRx Company Details
 Table 120. CytRx Business Overview
 Table 121. CytRx Drugs for Non-Small Cell Lung Cancer Product
 Table 122. CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 123. CytRx Recent Development
 Table 124. Eli Lilly Company Details
 Table 125. Eli Lilly Business Overview
 Table 126. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product
 Table 127. Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 128. Eli Lilly Recent Development
 Table 129. Exelixis Company Details
 Table 130. Exelixis Business Overview
 Table 131. Exelixis Drugs for Non-Small Cell Lung Cancer Product
 Table 132. Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 133. Exelixis Recent Development
 Table 134. Fresenius Kabi Company Details
 Table 135. Fresenius Kabi Business Overview
 Table 136. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product
 Table 137. Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 138. Fresenius Kabi Recent Development
 Table 139. Genentech Company Details
 Table 140. Genentech Business Overview
 Table 141. Genentech Drugs for Non-Small Cell Lung Cancer Product
 Table 142. Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 143. Genentech Recent Development
 Table 144. Hikma Pharmaceuticals Company Details
 Table 145. Hikma Pharmaceuticals Business Overview
 Table 146. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
 Table 147. Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 148. Hikma Pharmaceuticals Recent Development
 Table 149. Hospira Company Details
 Table 150. Hospira Business Overview
 Table 151. Hospira Drugs for Non-Small Cell Lung Cancer Product
 Table 152. Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 153. Hospira Recent Development
 Table 154. Intas Pharmaceuticals Company Details
 Table 155. Intas Pharmaceuticals Business Overview
 Table 156. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
 Table 157. Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 158. Intas Pharmaceuticals Recent Development
 Table 159. Karyopharm Therapeutics Company Details
 Table 160. Karyopharm Therapeutics Business Overview
 Table 161. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product
 Table 162. Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 163. Karyopharm Therapeutics Recent Development
 Table 164. Kyowa Hakko Kirin Company Details
 Table 165. Kyowa Hakko Kirin Business Overview
 Table 166. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product
 Table 167. Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 168. Kyowa Hakko Kirin Recent Development
 Table 169. Ligand Pharmaceuticals Company Details
 Table 170. Ligand Pharmaceuticals Business Overview
 Table 171. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
 Table 172. Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2020-2025) & (US$ Million)
 Table 173. Ligand Pharmaceuticals Recent Development
 Table 174. Research Programs/Design for This Report
 Table 175. Key Data Information from Secondary Sources
 Table 176. Key Data Information from Primary Sources
 Table 177. Authors List of This Report


List of Figures
 Figure 1. Drugs for Non-Small Cell Lung Cancer Picture
 Figure 2. Global Drugs for Non-Small Cell Lung Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Drugs for Non-Small Cell Lung Cancer Market Share by Type: 2024 VS 2031
 Figure 4. Radiofrequency Ablation (RFA) Features
 Figure 5. Radiation Therapy Features
 Figure 6. Chemotherapy Features
 Figure 7. Targeted Therapies Features
 Figure 8. Immunotherapy Features
 Figure 9. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application: 2024 VS 2031
 Figure 11. Hospitals Case Studies
 Figure 12. Clinics Case Studies
 Figure 13. Other Case Studies
 Figure 14. Drugs for Non-Small Cell Lung Cancer Report Years Considered
 Figure 15. Global Drugs for Non-Small Cell Lung Cancer Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Drugs for Non-Small Cell Lung Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region: 2024 VS 2031
 Figure 18. Global Drugs for Non-Small Cell Lung Cancer Market Share by Players in 2024
 Figure 19. Global Top Drugs for Non-Small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2024
 Figure 21. North America Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Drugs for Non-Small Cell Lung Cancer Market Share by Country (2020-2031)
 Figure 23. United States Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Drugs for Non-Small Cell Lung Cancer Market Share by Country (2020-2031)
 Figure 27. Germany Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Share by Region (2020-2031)
 Figure 35. China Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Drugs for Non-Small Cell Lung Cancer Market Share by Country (2020-2031)
 Figure 43. Mexico Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Share by Country (2020-2031)
 Figure 47. Turkey Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 51. GlaxoSmithKline Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 52. Menarini Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 53. Sanofi Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 54. Ziopharm Oncology Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 55. Alchemia Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 56. Amgen Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 57. Apotex Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 58. BioMarin Pharmaceutical Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 59. CellAct Pharma Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 60. Cerulean Pharma Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 61. Cipla Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 62. Cornerstone Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 63. Curis Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 64. CytRx Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 65. Eli Lilly Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 66. Exelixis Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 67. Fresenius Kabi Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 68. Genentech Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 69. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 70. Hospira Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 71. Intas Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 72. Karyopharm Therapeutics Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 73. Kyowa Hakko Kirin Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 74. Ligand Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2020-2025)
 Figure 75. Bottom-up and Top-down Approaches for This Report
 Figure 76. Data Triangulation
 Figure 77. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Non Small Cell Lung Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lung Cancer Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lung Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Squamous Non Small Cell Lung Cancer Therapeutics Market Research Report 2025
Global Targeted Drugs for NSCLC Market Research Report 2024
Lung Cancer Treatment Software Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Non melanoma Skin Cancer Drugs Market Research Report 2024
Oncology Anti cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Next Generation Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Non Hodgkin Lymphoma Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cancers Immunotherapy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lung Disease Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Solid Tumor Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lung Disease Therapeutic Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Prostate Cancer Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cancer Generics Market
Global Lung Cancer Diagnostic Tests Market Research Report 2024
Global Non invasive Cancer Diagnosis Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions